Summary
Government-wide OMB guidance that sets requirements and best practices for federal acquisition of AI systems and services, including planning, market research, evaluation criteria, contract terms, and post-award governance, with special attention to AI systems that are rights-impacting or safety-impacting and to alignment with existing AI-use guidance such as M-24-10.
Healthcare Implications
For HHS, CMS, CDC, NIH, VA, DoD health, and other health-related programs, this memorandum shaped how clinical decision-support tools, claims and fraud analytics, public-health surveillance systems, and other AI-enabled technologies were procured, pushing agencies to embed risk management, evaluation, transparency, and performance safeguards into contracts. It was subsequently rescinded and replaced by OMB Memorandum M-25-22.